Clinical Trial Update: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

View source ↗

Summary

Amgen's tarlatamab (AMG 757) expanded access protocol for advanced small cell lung cancer has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Cancer | Status: APPROVED_FOR_MARKETING